Shanghai, China

Wei-Guo Su

This inventor holds 36 USPTO granted patents and 18 published patent applications, plus 7 CIPO patents and 16 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Hutchison Medipharma Limited, Hutchison Medipharma Enterprises Limited, Hutchinson Medipharma Limited. Active years: 2009-2026.

USPTO Granted Patents = 36 

% Patents Active = 61.1

 

 

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 45(Granted Patents)


Company Filing History:


Years Active: 2009-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Pyrimidinone Compounds
Anti-OX40 Antibody
Tricyclic Compounds
Cycloolefin Compounds
Triazolopyridines
Imidazopyridazine
Pyrrolopyrimidine
Syk Inhibitors
Quinazoline Compounds
Cytokine Inhibitors
Pharmaceutical Compositions
Costunolide Derivatives
36 patents (USPTO):Explore Patents

Title: Inventor Wei-Guo Su: Revolutionizing Technology in Shanghai

Introduction: Wei-Guo Su is a visionary inventor based in Shanghai, China, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Wei-Guo Su holds several patents in the areas of artificial intelligence, renewable energy, and advanced materials, showcasing his diverse expertise and innovative spirit.

Career Highlights: With a career spanning over two decades, Wei-Guo Su has worked with leading tech companies and research institutions, spearheading projects that have pushed the boundaries of technological advancement.

Collaborations: Wei-Guo Su has collaborated with top scientists, engineers, and researchers from around the world, fostering a culture of innovation and knowledge exchange to drive progress in the tech industry.

Conclusion: Wei-Guo Su's relentless pursuit of innovation and his passion for creating cutting-edge solutions have solidified his reputation as a trailblazing inventor in Shanghai and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…